AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 116.7% in January

AstraZeneca PLC (OTCMKTS:AZNCF) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 127,400 shares, a growth of 116.7% from the December 31st total of 58,800 shares. Based on an average daily volume of 8,500 shares, the short-interest ratio is currently 15.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC purchased a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

AZNCF traded down $0.32 during trading on Friday, hitting $140.72. The company’s stock had a trading volume of 2,497 shares, compared to its average volume of 2,872. AstraZeneca has a twelve month low of $118.16 and a twelve month high of $175.00. The stock’s fifty day moving average price is $133.54 and its 200-day moving average price is $146.99.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.